Poor
Mostly Misaligned
Patient Risk:
Moderate
Summary
Most extracted claims are absent from FDA prescribing information (e.g., pricing, insurance/discounts, biosimilar market intent, patents/exclusivity). Only a minority of clinical/safety-related claims align, and several safety/adverse-reaction breadth statements are not fully anchored to labeled specifics.
Category Scores
Accurate Statements
Adalimumab is administered via subcutaneous injection.
Partially supported (label support marked partially_supported by provided evaluation).
Typical maintenance doses for adults often involve 40 mg injected every other week.
Supported (40 mg every other week appears in the provided dosage section for RA/PsA/AS).
Some patients may require weekly adalimumab injections depending on condition and response to treatment.
Supported (dose escalation to weekly exists in provided dosage section for RA patients not on concomitant MTX).
Adalimumab can increase the risk of serious infections.
Supported (boxed warning/Warnings and Precautions SERIOUS INFECTIONS).
Unsupported Statements
Adalimumab injection cost varies significantly based on dosage, geographic location, insurance coverage, and whether it is a branded or biosimilar product.
Absent from the label; pricing/market dynamics are not prescribing-information content.
Without insurance, the retail price for a single adalimumab injection can range from approximately $2,000 to over $6,000 for a 40 mg dose, depending on formulation and pharmacy.
Absent from the label; specific dollar price ranges are not FDA-labeled.
Without insurance, a 160 mg adalimumab starter pack might cost upwards of $12,000.
Absent from the label; starter pack pricing is not prescribing-information content.
Biosimilar versions of adalimumab have been introduced to the market.
Absent from the label; market availability statements are not FDA prescribing information for the reference product.
Biosimilar versions of adalimumab generally offer a lower price point compared to the originator brand Humira.
Absent from the label; comparative pricing is not FDA prescribing information.
Biosimilars are intended to increase market competition and reduce costs for patients and healthcare systems.
Absent from the label; policy/market intention statements are not FDA prescribing information.
Biosimilars are typically offered at a discount to Humira.
Absent from the label; typical discounting is not FDA-labeled.
Insurance coverage determines the patient's out-of-pocket expense for adalimumab.
Absent from the label; out-of-pocket cost determinants are not prescribing-information content.
Many insurance plans include co-pays or co-insurance for adalimumab.
Absent from the label; payer benefit design is not FDA prescribing information.
Patients may be subject to deductibles and formulary restrictions that can influence the final cost of adalimumab.
Absent from the label; formulary/cost-management details are not FDA prescribing information.
AbbVie offers patient assistance programs that may help reduce costs for eligible individuals.
Absent from the label; patient assistance availability is not FDA prescribing information.
For conditions like rheumatoid arthritis or Crohn's disease, an initial loading dose of adalimumab might be administered.
Absent from the provided label excerpts as a supported general statement; induction/loading regimens are indication-specific and were not provided in the supplied label text.
Adalimumab suppresses the immune system.
Absent from the label; broad mechanism phrased as 'suppresses the immune system' is not explicitly supported by the provided label excerpts.
Common side effects of adalimumab may include injection site reactions (redness, itching, swelling), upper respiratory infections, headache, and rash.
Absent from the label; specific 'common side effects' list is not supported by the provided label excerpts.
AbbVie has obtained additional patents that have extended adalimumab (Humira) market exclusivity for an extended period.
Absent from the label; patent/exclusivity status is not FDA prescribing information.
Contradictions
Important Omissions
No claims addressed core boxed-warning content explicitly (SERIOUS INFECTIONS and MALIGNANCY), including TB testing/monitoring and serious infection discontinuation guidance.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Several key statements required for label-anchored safety communication (boxed warning specifics such as TB evaluation/monitoring and malignancy warnings) were omitted, while multiple non-label cost/market claims may distract from safety-relevant prescribing information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Misaligned
Primary Issue
Majority of extracted claims are not supported by FDA prescribing information (especially pricing/insurance/biosimilar market and patent/exclusivity statements), and safety content central to the boxed warnings was not addressed.
Suggested Improvement
Limit claims to FDA label-supported clinical content (e.g., administration route, labeled dosing regimens, and boxed-warning safety elements such as serious infections/TB evaluation and malignancy warnings) rather than non-labeled market or pricing statements.